Send to:

Choose Destination
See comment in PubMed Commons below
Cancer Discov. 2013 Mar;3(3):255-7. doi: 10.1158/2159-8290.CD-13-0018.

Targeting MYCN: a good BET for improving neuroblastoma therapy?

Author information

  • 1Division of Oncology and the Center for Childhood Cancer Research. The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania 19104, USA.


Direct targeting of oncogenic MYC proteins has been an elusive goal of many cancer drug development efforts. In this issue of Cancer Discovery, Stegmaier and colleagues demonstrate that pharmacologically interfering with the bromodomain and extraterminal (BET) class of proteins potently depletes MYCN in neuroblastoma cells, resulting in cellular cytotoxicity and thus providing a novel approach with a potential impact on a previously undruggable major oncogene.

©2013 AACR.

Comment on

  • Targeting MYCN in neuroblastoma by BET bromodomain inhibition. [Cancer Discov. 2013]
[PubMed - indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Write to the Help Desk